Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain

Leukemia & Lymphoma
Roberta RiccioniUgo Testa

Abstract

In a previous study we have shown that the interleukin-3 receptor alpha chain (IL-3Ralpha) is over expressed in about 45% of acute myeloid leukemias (AMLs) and this phenomenon was associated with high blast cell counts at diagnosis, high rate of cycling of leukemic blasts and with a worse prognosis. Here we have investigated the immunophenotypic features of 125 AML patients subdivided into three groups (IL-3R(high), IL-3R(middle) and IL-3R(low)) according to the level of IL-3Ralpha expression. AMLs over expressing the IL-3Ralpha represent a subgroup of AMLs with a peculiar immunophenotype mainly consisting in the elevated expression of CD34 and several receptor membrane tyrosine kinases, such as c-kit and flt3, and in a usually low expression of myeloid-associated antigens such as CD11b, CD14 and CD15. These findings suggest that IL-3Ralpha + + + AMLs are blocked at an early stage of differentiation and express at elevated levels several growth factor receptors. It is proposed that these findings may further help to understand the mechanisms involved in the development of high-risk acute leukemias.

References

Aug 30, 2001·Proceedings of the National Academy of Sciences of the United States of America·Y YuanD E Zhang
Dec 4, 2001·Nature Genetics·Scott A ArmstrongStanley J Korsmeyer
Jun 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Louise M KellyD Gary Gilliland
Nov 15, 2002·The New England Journal of Medicine·William C Hahn, Robert A Weinberg
Nov 27, 2002·Proceedings of the National Academy of Sciences of the United States of America·Monica L GuzmanCraig T Jordan
Feb 4, 2003·Nature Reviews. Cancer·Daniel G Tenen
Feb 8, 2003·Current Opinion in Genetics & Development·James R Downing
Apr 12, 2003·Leukemia·M WetzlerM R Baer
Apr 30, 2003·Cytometry. Part B, Clinical Cytometry·R ReppUNKNOWN AML-SHG Study Group
Sep 3, 2003·Nature Reviews. Cancer·Derek L Stirewalt, Jerald P Radich
Sep 25, 2003·Proceedings of the National Academy of Sciences of the United States of America·Emmanuelle PasseguéIrving L Weissman

❮ Previous
Next ❯

Citations

Jun 29, 2012·Protein Engineering, Design & Selection : PEDS·Shu-Ru KuoJen-Sing Liu
Jun 12, 2010·IUBMB Life·Angel F LopezMichael W Parker
Dec 11, 2013·British Journal of Haematology·Robin E GasiorowskiDerek N J Hart
Aug 30, 2016·The Journal of Clinical Investigation·Marco RuellaSaar Gill
Sep 27, 2014·World Journal of Stem Cells·Jianbiao Zhou, Wee-Joo Chng

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.